GSK disputes '60 Minutes' report's implication of harm
This article was originally published in Scrip
GlaxoSmithKline strongly rebutted implications made in the CBS TV programme 60 Minutes that patients were harmed as a result of manufacturing violations at its now-closed Cidra, Puerto Rico facility. The CBS programme reported 2 January more details about the $750 million GSK agreed to pay in October 2010 to settle US charges of manufacturing and distribution of adulterated drugs. GSK said it regretted the manufacturing violations at the facility highlighted in the CBS report, and emphasised that the problems took place between 2001 and 2005 and involved only one of the firm's manufacturing sites, which was run by its subsidiary SB Pharmco Puerto Rico.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.